NCT03083431View on ClinicalTrials.gov

Oral Propranolol for Prevention of Threshold Retinopathy of Prematurity

PHASE2RecruitingINTERVENTIONAL
Enrollment

276

Participants

Timeline

Start Date

September 22, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

July 31, 2026

Conditions
Retinopathy of Prematurity
Interventions
DRUG

Propranolol

Oral propranolol (1.6 mg propranolol-hydrochloride/kg/d in 4 divided dosages)

DRUG

Placebo

Oral solution containing the same excipients as propranolol solution

Trial Locations (3)

8091

RECRUITING

University Hospital Zurich, Zurich

72076

RECRUITING

University Hospital Tübingen, Tübingen

06590

RECRUITING

Ankara University School of Medicine Children's Hospital, Ankara

All Listed Sponsors
collaborator

Ankara University

OTHER

collaborator

University Hospital Tuebingen

OTHER

lead

University of Zurich

OTHER